These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30504329)

  • 21. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Ansell J; Hirsh J; Hylek E; Jacobson A; Crowther M; Palareti G
    Chest; 2008 Jun; 133(6 Suppl):160S-198S. PubMed ID: 18574265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs).
    van Gorp RH; Schurgers LJ
    Nutrients; 2015 Nov; 7(11):9538-57. PubMed ID: 26593943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Portuguese Observational Study of Ischaemic Stroke in Patients Medicated with Non-Vitamin K Antagonist Oral Anticoagulants.
    Beato-Coelho J; Marto JP; Alves JN; Marques-Matos C; Calado S; Araújo J; Cunha L; Pinho J; Azevedo E; Viana-Baptista M; Sargento-Freitas J
    Eur Neurol; 2018; 79(1-2):108-112. PubMed ID: 29421803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
    Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
    Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Argentine Consensus in effective management of anticoagulation clinics for the use of vitamin k antagonists].
    Ceresetto JM; Duboscq C; Korin J; Fondevila C; Casais P; Rossi A; Scazziota A; Martinuzzo M; Aris Cancela ME; Rosa C; Pombo G; Guimelli C; Adamczuk Y; Martí A; Penchasky D; Riveros D; Puente D; Celebrin L; Molnar S; Meschengieser S; Castro Ríos M; Blanco A; Hendler H; Brodsky A; Sánchez Luceros A; Negri Aranguren P; Fedele JL; Merlo C; Raña P; Gumpel C; Colorio C; Grand B; Canónico V; Rossi E; Colimodio P; Orlando S; Fassi D; Arias M; Viudez L; Farreras R; Martínez P; Ferro H; Casali C; Baques A; Arbesú G; Viñuales S; Medina F; Cortés V; Gallo MDC; Ehelou L; Barrera L; Rey I; de Larrañaga G; Figueroa F; Vilaseca A; Kuri I; Maneyro A; Otaran M; Xavier DL; Garbiero S; Salviú J; Fontenla P; Eckhardt A; Bomparola C; Fornasiero L
    Medicina (B Aires); 2020; 80 Suppl 4():1-26. PubMed ID: 32897867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral anticoagulant monitoring: Are we on the right track?
    Onundarson PT; Flygenring B
    Int J Lab Hematol; 2019 May; 41 Suppl 1():40-48. PubMed ID: 31069986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of the knowledge of patients about the management of treatment with anti-vitamin K drugs in the Service of Cardiology of Ouagadougou].
    Samadoulougou AK; Naibe DT; Mandi DG; Kabore E; Millogo GR; Yameogo NV; Kologo JK; Tall AT; Toguyeni BJ; Zabsonre P
    Ann Cardiol Angeiol (Paris); 2015 Sep; 64(4):263-7. PubMed ID: 26275496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study.
    Denas G; Gennaro N; Ferroni E; Fedeli U; Saugo M; Zoppellaro G; Padayattil Jose S; Costa G; Corti MC; Andretta M; Pengo V
    Int J Cardiol; 2017 Dec; 249():198-203. PubMed ID: 28935464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors of vitamin K antagonist overcoagulation.
    Marie I; Leprince P; Menard JF; Tharasse C; Levesque H
    QJM; 2012 Jan; 105(1):53-62. PubMed ID: 21880698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics of vitamin K antagonists: useful or hype?
    Lippi G; Franchini M; Favaloro EJ
    Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [What is the current use of vitamin K antagonists in the elderly?].
    Vidal JS; Hanon O
    Geriatr Psychol Neuropsychiatr Vieil; 2013 Dec; 11(1 Suppl):17-22. PubMed ID: 24463060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Novel oral anticoagulants and atrial fibrillation in the elderly].
    Hanon O
    Geriatr Psychol Neuropsychiatr Vieil; 2013 Dec; 11(1 Suppl):34-40. PubMed ID: 24463062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.
    Seiffge DJ; Hooff RJ; Nolte CH; Béjot Y; Turc G; Ikenberg B; Berge E; Persike M; Dequatre-Ponchelle N; Strbian D; Pfeilschifter W; Zini A; Tveiten A; Næss H; Michel P; Sztajzel R; Luft A; Gensicke H; Traenka C; Hert L; Scheitz JF; De Marchis GM; Bonati LH; Peters N; Charidimou A; Werring DJ; Palm F; Reinhard M; Niesen WD; Nagao T; Pezzini A; Caso V; Nederkoorn PJ; Kägi G; von Hessling A; Padjen V; Cordonnier C; Erdur H; Lyrer PA; Brouns R; Steiner T; Tatlisumak T; Engelter ST;
    Circulation; 2015 Sep; 132(13):1261-9. PubMed ID: 26232277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approaches to optimal dosing of vitamin K antagonists.
    Witt DM
    Semin Thromb Hemost; 2012 Oct; 38(7):667-72. PubMed ID: 22893509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Old and new oral anticoagulants: Food, herbal medicines and drug interactions.
    Di Minno A; Frigerio B; Spadarella G; Ravani A; Sansaro D; Amato M; Kitzmiller JP; Pepi M; Tremoli E; Baldassarre D
    Blood Rev; 2017 Jul; 31(4):193-203. PubMed ID: 28196633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.